Ferring Pharmaceuticals, Inc.
400 Rella Boulevard
Suffern
New York
10901
United States
Tel: 914-333-8900
Website: http://www.ferringusa.com/
47 articles with Ferring Pharmaceuticals, Inc.
-
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
-
FDA Approves New Indications for ZOMACTON® (somatropin) as Ferring Plans Launch of Needle-Free Delivery System
7/19/2018
Ferring Pharmaceuticals, Inc.. today announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for injection in four additional pediatric indications:
-
The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.
-
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area. -
New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment
7/2/2018
Rekovelle’s unique dosing algorithm, which is based on a woman’s anti-Müllerian hormone (AMH) level and body weight, is designed for predictable ovarian response
-
NOCDURNA® (desmopressin acetate) Now Approved by U.S. FDA as First Sublingual Tablet to Treat Nocturia due to Nocturnal Polyuria
6/21/2018
The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market NOCDURNA®.
-
Male Fertility Survey Reveals 80 Percent of Men Feel Overlooked When Experiencing Infertility Challenges
6/11/2018
Ferring Pharmaceuticals Inc. (US) has announced findings from a survey conducted with RESOLVE: The National Infertility Association to better understand how men feel when struggling with their own or their partner’s infertility.
-
Ferring to Present Clinical Data on Efficacy and Safety of CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep at Digestive Disease Week
6/5/2018
Tuesday, June 5, 12:00-2:00 p.m., Dr. Lawrence Hookey to present "A Randomized, Assessor-Blinded, Multicenter Study Demonstrates the Efficacy and Safety of a New Ready-to-Drink Low Volume Bowel Preparation Prior to Colonoscopy" (Poster # Tu2010)
-
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
-
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
-
Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.
4/5/2018
Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product
-
March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London
3/7/2018
-
Enteris BioPharma Initiates Feasibility Program with Ferring Pharmaceuticals to Develop an Oral Formulation of a Peptide
3/5/2018
Agreement to Target New Oral Peptide Development Opportunity, Extending Successful Relationship between Enteris and Ferring
-
Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage
2/22/2018
The CHAMPION trial is assessing the effectiveness and safety of heat-stable carbetocin vs. oxytocin, the current standard of care, for preventing PPH after vaginal birth
-
Ferring Announces 30M CHF Investment in New Biotech Centre in Switzerland
2/14/2018
Ferring announced today that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland.
-
Ferring's CLENPIQ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep Now Available
2/12/2018
Colorectal cancer is the third most common cancer and second leading cause of cancer death in the United States.
-
Ferring's ZOMACTON (somatropin) for Injection Receives FDA Approval to Treat Growth Hormone Defic...
2/1/2018
Ferring today announced that the FDA has approved ZOMACTON for Injection 5 mg and 10 mg recombinant human growth hormone indicated for replacement of GH in adults with GH deficiency. -
Ferring Announces Recipients of Innovation Grants Program 2017-2018
1/26/2018
Ferring Pharmaceuticals today announced the recipients of the 2017-2018 Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego.
-
Ligand Enters into Worldwide OmniAb Platform License Agreement with Ferring Pharmaceuticals
1/22/2018
Under the license, Ferring will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies.
-
Ferring Enters Into Worldwide OmniAb Platform License Agreement With Ligand
1/22/2018
Under the agreement, Ferring will use OmniAb to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology.